Elevance Health Challenges Medicare Advantage Star Ratings

Elevance Health has taken legal action against the Centers for Medicare & Medicaid Services (CMS) and the Department of Health and Human Services (HHS), challenging the legitimacy of 11 measures used in calculating its 2027 Medicare Advantage star ratings. This lawsuit threatens approximately $516 million in quality bonus payments and rebate retention for 2028.

On November 6, 2026, Elevance Health filed the complaint in the U.S. District Court for the District of Columbia, alleging that the measures in question were adopted without following the formal rulemaking process mandated by Congress. This legal confrontation underscores the critical financial stakes for Medicare Advantage plans, as star ratings influence rebate retention and eligibility for quality bonus payments.

Operational and Financial Ramifications

The disputed measures allegedly reduced star ratings for 12 contracts across several states, including New Jersey, Ohio, California, and Texas, and affected one national contract. Elevance Health argues that removing these measures would result in an increase of at least half a star for each contract. Attaining higher star ratings could substantially enhance the company’s financial performance through increased bonus payments.

Medicare Advantage plans submit annual bids to CMS, with rebates influenced by star ratings. Currently, plans rated below 3.5 stars retain 50% of the rebate. Ratings of 3.5 to below 4.5 stars allow for a 65% retention, while plans at 4.5 stars or above keep 70%. Elevance argues that some contracts could exceed the 4-star mark if the contentious measures were excluded, positively impacting rebate retention percentages.

Regulatory and Industry Context

This case draws attention to regulatory inconsistencies in CMS’s rating methodologies. Notably, a similar May 2026 ruling in Georgia found certain CMS methodologies unlawful in the Clover Insurance Co. v. HHS case. CMS recalibrated Clover’s star ratings following the ruling but retained the same measures for Elevance’s calculations. Elevance contests this inconsistency and seeks adjustments to its ratings.

The legal challenge also disputes specific measures related to medication adherence, contending that these rely on unauthorized data sources for calculating star ratings. Elevance aims for these measures to be excluded, advocating for a recalculation of 2027 ratings and corresponding adjustments to 2028 payments.

Implications for Industry Professionals

Elevance Health’s lawsuit underscores significant concerns regarding the transparency and consistency of CMS’s star rating calculations. For insurance professionals, understanding the implications of this case is crucial. Star ratings dramatically influence plan marketing, broker recommendations, and market competition. The outcome could lead to adjustments in CMS’s criteria for evaluation, affecting the broader landscape of Medicare Advantage plans.

Star Rating Rebate Retention
Below 3.5 Stars 50% of rebate retention
3.5 to Below 4.5 Stars 65% of rebate retention
4.5 Stars and Above 70% of rebate retention

As the case proceeds, insurance agents, brokers, and claims professionals should monitor developments closely. A ruling in favor of Elevance could prompt regulatory changes and recalibrations of ratings, reshaping Medicare Advantage plan strategies and influencing future compliance requirements.